Get started
Torrent Pharmaceuticals LtdTorrent Pharmaceuticals LtdTorrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

TORNTPHARM trade ideas

Torrent Pharma – Steady Growth with Strong Margins📈Technical Analysis The stock has shown a powerful uptrend over the past 5–6 years, with a sharp rally from ₹1,000 to ₹3,500. For the past year, the ₹3,500–₹3,600 zone stood strong as resistance. With the release of the positive Q1 FY26 results, Torrent has decisively broken above this supply zone accompanied by higher volumes—something not seen earlier this year. After the breakout, prices rose to ₹3,800 and then retested the broken zone, which now appears to be offering support. Provided this zone continues to hold and is followed by bullish candlestick confirmation, the stock looks set for further upside. Targets: 🎯 ₹3,800 (Target 1) 🎯 ₹3,900 (Target 2) 🎯 ₹4,000 (Target 3) Stop Loss: Below the support zone at ₹3,400. If prices fall below this, bullish outlook is invalidated. 💰Q1 FY26 Financial Highlights (vs Q4 FY25 & Q1 FY25) Total Income: ₹3,178 Cr (↑ +7.4% QoQ vs ₹2,959 Cr; ↑ +11.2% YoY vs ₹2,859 Cr) Total Expenses: ₹2,146 Cr (↑ +7.6% QoQ vs ₹1,995 Cr; ↑ +9.8% YoY vs ₹1,955 Cr) Operating Profit: ₹1,032 Cr (↑ +7.0% QoQ vs ₹964 Cr; ↑ +14.2% YoY vs ₹904 Cr) Profit Before Tax: ₹738 Cr (↑ +11.0% QoQ vs ₹665 Cr; ↑ +12.5% YoY vs ₹656 Cr) Profit After Tax: ₹548 Cr (↑ +10.0% QoQ vs ₹498 Cr; ↑ +19.9% YoY vs ₹457 Cr) Diluted EPS: ₹16.19 (↑ +10.1% QoQ vs ₹14.71; ↑ +19.9% YoY vs ₹13.50) This performance reflects robust execution across both domestic and international markets. 🧠Fundamentals & Strategic Highlights Domestic Market Strength: India revenues grew ~11%, driven by outperforming chronic therapies (13% growth vs 9% IPM growth) Global Growth: US business expanded by ~19% Brazil saw 11% growth Analyst Sentiment: Citi raised its target price to ₹4,380, citing sustained margin expansion and branded portfolio gains M&A Plans: Torrent is acquiring a majority stake in JB Chemicals for ₹18,000–₹19,500 Cr, positioning the company among India’s top five pharma giants ✅Conclusion Torrent Pharma’s technical breakout, backed by a wholesome Q1 performance and strategic M&A moves, positions it favorably for renewed upside. A failure to hold above ₹3,500 would challenge this view. Disclaimer: lnkd.in
NSE:TORNTPHARM
by ALICEBLUE
Torrent Pharma – Steady Growth with Strong Margins📈 Technical Analysis The stock has shown a powerful uptrend over the past 5–6 years, with a sharp rally from ₹1,000 to ₹3,500. For the past year, the ₹3,500–₹3,600 zone stood strong as resistance. With the release of the positive Q1 FY26 results, Torrent has decisively broken above this supply zone accompanied by higher volumes—something not seen earlier this year. After the breakout, prices rose to ₹3,800 and then retested the broken zone, which now appears to be offering support. Provided this zone continues to hold and is followed by bullish candlestick confirmation, the stock looks set for further upside. Targets: 🎯 ₹3,800 (Target 1) 🎯 ₹3,900 (Target 2) 🎯 ₹4,000 (Target 3) Stop Loss: Below the support zone at ₹3,400. If prices fall below this, bullish outlook is invalidated. 💰 Q1 FY26 Financial Highlights (vs Q4 FY25 & Q1 FY25) Total Income: ₹3,178 Cr (↑ +7.4% QoQ vs ₹2,959 Cr; ↑ +11.2% YoY vs ₹2,859 Cr) Total Expenses: ₹2,146 Cr (↑ +7.6% QoQ vs ₹1,995 Cr; ↑ +9.8% YoY vs ₹1,955 Cr) Operating Profit: ₹1,032 Cr (↑ +7.0% QoQ vs ₹964 Cr; ↑ +14.2% YoY vs ₹904 Cr) Profit Before Tax: ₹738 Cr (↑ +11.0% QoQ vs ₹665 Cr; ↑ +12.5% YoY vs ₹656 Cr) Profit After Tax: ₹548 Cr (↑ +10.0% QoQ vs ₹498 Cr; ↑ +19.9% YoY vs ₹457 Cr) Diluted EPS: ₹16.19 (↑ +10.1% QoQ vs ₹14.71; ↑ +19.9% YoY vs ₹13.50) This performance reflects robust execution across both domestic and international markets. 🧠 Fundamentals & Strategic Highlights Domestic Market Strength: India revenues grew ~11%, driven by outperforming chronic therapies (13% growth vs 9% IPM growth) Global Growth: US business expanded by ~19% Brazil saw 11% growth Analyst Sentiment: Citi raised its target price to ₹4,380, citing sustained margin expansion and branded portfolio gains M&A Plans: Torrent is acquiring a majority stake in JB Chemicals for ₹18,000–₹19,500 Cr, positioning the company among India’s top five pharma giants ✅ Conclusion Torrent Pharma’s technical breakout, backed by a wholesome Q1 performance and strategic M&A moves, positions it favorably for renewed upside. A failure to hold above ₹3,500 would challenge this view. ⚠️ Disclaimer: This report is for informational purposes only and does not constitute investment advice. Please consult a financial advisor before making any investment decisions.
NSE:TORNTPHARMLong
by Rupesh_Chidharala
1
Torrent Pharma to touch 3100 again ?Torrent Pharma is in corrective phase for a while. This correction is not going to end anytime soon, however we still have opportunity to make some money here. Currently on the Daily chart its in complex correction in which we have already completed Wave W, what's left is Wave X and Wave Y. Once we are good with the completion of wave X then expect it to unfold in a-b-c which will be part of wave Y. Disclaimer: I am not SEBI registered member, this is only for educational purpose only.
NSE:TORNTPHARM
by Swiftstrike
TORNTPHARM : Consolidation BreakoutStock is showing consolidation Breakout on ATH level, which is good for stock. Depends on its upcoming results the rally will be continue. Showing Head and Shoulder Breakout All data is available in public domain.. CMP : 3600 TG : 4200 SL : 3290 Stock's selection based on 5 Point Analysis: 1: Idea : Breakout. 2: Support : Volume, Delivery . 3: Technical : 21/55/200-EMA, Super trend up, RS>0 RSI. 4: Fundamental : PE, PAT, Industry & peer PE and sector performance. 5: Timing : Entry Timing on Daily chart. Disclaimer : It is my personal view as a trader and for educational purpose only. Equity market involves risk . Please consult your financial adviser before taking any decision.
NSE:TORNTPHARMLong
by SthitaprajnaYogi
2
TORRENT PHARMACEUTICALS LTD. (TORPHARM) View: Bullish on confirmed breakout. Bias: Positive momentum building. Strategy: BUY: Above ₹3600 (on weekly closing basis with strong volume confirmation). Targets (T): T1: ₹3750 T2: ₹3950+ Stop-Loss (SL): ₹3400 (on weekly closing basis). Reasoning: Strong support at ₹3000-₹3050. Challenging multi-month descending trendline resistance. Positive RSI divergence and increasing volume. Potential for a significant trend reversal if breakout is confirmed.
NSE:TORNTPHARMLong
by rmhetre15
Symmetrical Triangle pattern in Torrent Pharma Symmetrical Triangle Breakout Setup Torrent Pharmaceuticals Ltd (TORNTPHARM) Breakout Level: ₹3,300 Stop Loss: ₹3,150 (below triangle support) Target: ₹4,000 (based on height of triangle) Risk:Reward: ~2.8:1 ✅ Technical Confirmation: RSI near 52 — momentum shifting bullish above 55. MACD positive crossover, rising histogram — trend strength improving. Volume: Awaiting breakout candle with above-average volume for confirmation. EFI (Elder Force Index) turning positive — signals potential surge in buying force. 📌 Strategy Insight: A breakout above ₹3,300, backed by volume and momentum, could lead to a sharp trend continuation toward ₹4,000. The symmetrical triangle represents consolidation after trend — a potential bullish continuation pattern.
NSE:TORNTPHARMLong
by Punit190
1
Torrent Pharma: Channel range targets.On the daily chart, Torrent Pharma is forming a channel, which has given a rejection on the upper channel line. Now the immediate support range is between 3093.70 and 3074, where a short side entry is possible on breakdown for the target of the lower channel line. Inside the bigger picture, below the support range, the price will complete the channel and target the lower line of the channel. If this support is not breached, there is a higher chance of a bullish breakout from the upper channel.
NSE:TORNTPHARMShort
by AbsoluteAnalytics
TORNTPHARM Final Bearish move before bulls entry????Yesssss!!!! Chart patterns suggest me the above titled opinion... TORNTPHARM has been travelling in a Ascending Expanding channel pattern IN A BULLISH MODE MAKING SERIES OF HIGHER HIGHS AND HIGHER LOWS... (shown below) Inside the bullish pattern , it is now currently in the downward phase that too inside rectangular descending channel pattern making a SERIES OF LOWER HIGHS AND LOWER LOWS.... It's moving like a written script till now....let's wait and watch whether the director(market) has any twist in the script or not!!! This is just my opinion....not a tip nor advice!!!! Thank you!!!!!!!
NSE:TORNTPHARMShort
by mmjimm
## TORNTPHARM Price AnalysisTorrent Pharmaceuticals (TORNTPHARM) is currently trading near ₹3,254, maintaining a strong uptrend over the past several years. The stock has delivered a return of approximately 165% from July 2020 to November 2024, including a stock split, highlighting its consistent long-term growth. **Valuation and Fair Value** TORNTPHARM is trading well above its estimated intrinsic value. Independent valuations suggest a fair value in the range of ₹1,560 to ₹1,940 per share, meaning the current market price is overvalued by about 40%. The price-to-earnings (PE) ratio stands at approximately 59–66, which is significantly higher than the sector average of around 49, indicating a premium valuation. The price-to-book (PB) ratio is also elevated at 16, compared to the sector average of 6.29. **Recent Performance** The stock has shown positive momentum in the short term, with returns of 3.5% over the past week and 5.7% over the past month. Over the last year, TORNTPHARM has gained nearly 28%, and over three years, the return is more than 128%. Despite some volatility, the stock has outperformed many of its peers and the broader market. **Fundamental Trends** Torrent Pharma’s India business, which constitutes the bulk of its revenue, grew by 12% in Q3 FY25, driven by strong performance in branded generics. However, the company faces challenges in international markets, particularly the US, due to regulatory headwinds and pricing pressures. Revenue growth over the past five years has averaged 7% annually, slightly below the industry average, but net income growth has been robust at over 30% per year, outpacing peers. **Analyst Outlook** Analysts have a moderately positive outlook, with a one-year price target averaging around ₹3,600, and a range between ₹2,959 and ₹4,200 . About 68% of analysts currently rate the stock as a buy. **Dividend and Market Cap** The dividend yield is 0.86%, which is above the sector average, and the company’s market capitalization is approximately ₹1.1 lakh crore, placing it among the larger players in the Indian pharmaceutical sector. **Summary** TORNTPHARM has demonstrated strong long-term price appreciation and profitability, but it is currently trading at a significant premium to its estimated intrinsic value. Short-term technicals are mixed, with some bullish undertones, but caution is warranted due to high valuation multiples. The company’s growth is primarily driven by its domestic business, while international operations face ongoing challenges. Analyst sentiment remains positive, but the upside may be limited unless earnings growth accelerates or valuation multiples contract.
NSE:TORNTPHARMLong
by KamalKJoshi
Looks like a good long opportunityThe stock has potentially broken above the short-term descending trendline, signaling a bullish reversal. Current support is near ₹3,180, with resistance at ₹3,320 (recent high). A sustained move above ₹3,320 could target ₹3,450 or higher if momentum continues. Entry: Enter a long position if the price holds above ₹3,200 Stop Loss: Place a stop loss below ₹3,170 to protect against a false breakout. Target: Initial target at ₹3,320, with a secondary target around ₹3,400, based on recent highs and price forecasts. Risk Management: Watch for broader market trends and pharma sector performance, as tariffs could impact sentiment.
NSE:TORNTPHARMLong
by aravindnc
1
TORNTPHARM Bullish Breakout: Targeting ₹3300 & ₹3400 from CMP ₹Current Market Price (CMP): ₹3245 Target 1 (T1): ₹3300 Target 2 (T2): ₹3400 Stop Loss (SL): ₹3180 (below recent swing low for risk management) Timeframe: Daily/Weekly Trade Type: Long (Buy) Technical Analysis Trend Analysis: - TORNTPHARM is in a steady uptrend, supported by higher highs and higher lows on the daily chart. - The stock is trading above its 50-day and 200-day EMAs, indicating bullish momentum. Key Levels: - Support: ₹3200–₹3180 (recent swing low and near 50-day EMA). - Resistance: ₹3300 (psychological level and minor resistance), ₹3400 (previous high and key resistance zone). - A breakout above ₹3300 could accelerate momentum toward ₹3400. Indicators: Chart Patterns: - The stock is forming a bullish continuation pattern (consolidation near highs), with a potential breakout above ₹3250–₹3270. - A strong close above ₹3250 could confirm the move toward T1 and T2. Trade Setup Entry: Buy at CMP ₹3245 or on a breakout above ₹3250 with strong volume. - Target 1: ₹3300 (1.7% upside, short-term target). - Target 2: ₹3400 (4.8% upside, medium-term target). - Stop Loss: ₹3180 (1.9% downside risk, below support zone). - Risk-Reward Ratio: ~1:2.5 (favorable for swing trading). Rationale - TORNTPHARM is benefiting from strong fundamentals in the pharmaceutical sector, with consistent revenue growth and positive market sentiment. - Technicals indicate a continuation of the bullish trend, with ₹3300 and ₹3400 as achievable targets based on prior resistance levels. - The stop loss at ₹3180 protects against a potential trend reversal or pullback to stronger support. Risk Management - Position size: Limit risk to 1–2% of capital based on the ₹65 stop loss (₹3245 - ₹3180). - Monitor for high volatility around key resistance levels (₹3300 and ₹3400). - Exit if the stock breaks below ₹3180 on a daily close or shows signs of bearish divergence on RSI/MACD. Additional Notes - Sector Context: The Indian pharma sector is showing resilience due to export growth and domestic demand. TORNTPHARM’s strong product portfolio supports the bullish outlook. - News Catalyst: Keep an eye on quarterly earnings or regulatory updates that could impact price movement. - Time Horizon: 2–4 weeks for T1, 4–8 weeks for T2, depending on market conditions. Disclaimer: This is not financial advice. Conduct your own research and consult a financial advisor before trading. Past performance does not guarantee future results.
NSE:TORNTPHARMLong
by aravindnc
Inverse H&S Forming on Daily TF – on #TorrentPharmaInverse H&S Forming on Daily TF – Price Testing Resistance Trendline. What’s Next? An Inverse Head & Shoulders (H&S) pattern is taking shape on the daily chart, suggesting a potential bullish reversal. Price is now testing a key resistance trendline—will it break through? 🔹 Bullish Confirmation: A breakout above resistance could confirm the pattern, targeting higher levels. 🔹 Bearish Rejection: If price gets rejected, the setup may fail, leading to a retest of nearest support. Key Levels: Neckline (resistance) & trendline breakout zone. Thoughts? #PriceAction #TradingSetup
NSE:TORNTPHARMLong
by Alert_Trader
1
TORNTPHARM for 2800?TORNTPHARM CMP 3205 Observations: Price broke down from a 3 months consolidation and Retesting the breakdown levels at 3290-3320 Price is trading below the Cloud on Daily TF, Future Cloud is Negative In shorter TF, it looks like a Rounding TOP formation and breakdown.. Suggesting 2800 levels (If you plot the chart on invert scale you will understand it better.. A retest of the breakdown level at 3300 level is due.. which is also the 50% retracement of this recent fall.. between 50 and 61%, it is a good risk reward set up for the short trade.. Note: I am not a SEBI Registered Analyst. Charts are for Educational purpose only.
NSE:TORNTPHARMShort
by Murthy_Santhosh
Flag and Pole Pattern with 20 WEMA SetupNSE:TORNTPHARM has made a Pole and Flag Pattern on a Weekly Timeframe with 20 WEMA on the lower edge of the flag. If a Bullish flag pattern Breaks Out above 3600, the stock may move toward the pattern target after the breakout which is 4560. Keep a Stop Loss of 3250. NSE:TORNTPHARM is a leading Indian Pharmaceutical Company engaged in the research, development, manufacturing and marketing of generic pharmaceutical formulations, and gave a good Q2 FY 24-25 Resluts Recently. 🙋‍♀️🙋‍♂️If you have any questions about this stock, feel free to reach out to me. 📌Thank you for exploring my idea! I hope you found it valuable. 🙏FLLOW for more 👍BOOST if useful ✍️COMMENT Below your views. Meanwhile, check out my other stock ideas below until this trade is activated. I would love your feedback. Disclaimer: This analysis is intended solely for informational and educational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions.
NSE:TORNTPHARMLong
by Karanshah137
Torrent PharmaAll important points are marked. 𝐃𝐢𝐬𝐜𝐥𝐚𝐢𝐦𝐞𝐫: 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐫𝐞 𝐬𝐮𝐛𝐣𝐞𝐜𝐭 𝐭𝐨 𝐦𝐚𝐫𝐤𝐞𝐭 𝐫𝐢𝐬𝐤𝐬, 𝐫𝐞𝐚𝐝 𝐚𝐥𝐥 𝐭𝐡𝐞 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐝𝐨𝐜𝐮𝐦𝐞𝐧𝐭𝐬 𝐜𝐚𝐫𝐞𝐟𝐮𝐥𝐥𝐲 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐧𝐠. 𝐒𝐭𝐨𝐜𝐤𝐬 𝐬𝐮𝐠𝐠𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐠𝐫𝐨𝐮𝐩 𝐚𝐫𝐞 𝐟𝐨𝐫 𝐞𝐝𝐮𝐜𝐚𝐭𝐢𝐨𝐧 𝐩𝐮𝐫𝐩𝐨𝐬𝐞. 𝐖𝐞 𝐝𝐨𝐧𝐭 𝐦𝐚𝐤𝐞 𝐚𝐧𝐲 𝐩𝐫𝐨𝐟𝐢𝐭𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐢𝐬 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠 𝐬𝐡𝐚𝐫𝐞𝐝 𝐡𝐞𝐫𝐞 𝐚𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐥𝐲 𝐨𝐟 𝐟𝐫𝐞𝐞 𝐨𝐟 𝐜𝐨𝐬𝐭.
NSE:TORNTPHARMLong
by sreekumars